Pseudodrynaria Coronana (Wall) Ching

• Status: Completed
• Trial end date: 2001-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The Study to evaluate the clinical effect of "Gusuibu" lasts for 3 years. It aims to evaluate its effect on bone density of postmenopausal osteoporosis. Besides, its effects on the liver, kidney and the hematological influence will be evaluated, too.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Collaborator: Sheng Chang Pharmaceutical

Criteria

Inclusion Criteria:

• postmenopausal osteoporosis

Exclusion Criteria:

• Insulin dependent diabetes